Agios to Participate in September Investor Conferences
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ: AGIO) announces its participation in two September investor conferences. The company will present at the Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET, followed by the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET. Live webcasts can be accessed on Agios' website, with replays available for two weeks post-event. Agios specializes in developing therapies for rare diseases, including a first-in-class treatment for pyruvate kinase deficiency and ongoing programs in various hematological conditions.
Positive
- None.
Negative
- None.
News Market Reaction – AGIO
In the trading session that priced this news, AGIO gained 6.42%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:
- Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and
- Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m. ET.
Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare and genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com
